Catalog No.: PC-21177Not For Human Use, Lab Use Only.
MyD88 inhibitor C17 is a highly potent inhibitor of myeloid differentiation primary response protein 88 (MyD88), dose-dependently inhibits LPS-induced IL-6 and TNF-α in J774A.1 macrophages with IC50 of 2.17 and 8.17 uM, respectively.
MyD88 inhibitor C17 is a highly potent inhibitor of myeloid differentiation primary response protein 88 (MyD88), dose-dependently inhibits LPS-induced IL-6 and TNF-α in J774A.1 macrophages with IC50 of 2.17 and 8.17 uM, respectively.
MyD88 inhibitor C17 directly interacts with MyD88 in a dose-dependent manner with Kd of 53 uM in SPR assays.
MyD88 inhibitor C17 also shows inhibition on the release of cytokines in LPS-stimulated human THP-1 cells, suppresses TLR-MyD88 signaling in response to LPS stimulation.
MyD88 inhibitor C17 inhibits the interaction of TLR4 and MyD88 and suppressed the NF-κB pathway.
MyD88 inhibitor C17 treatment (20 mg/kg, orally) led to the accumulation in the lungs of rats and attenuated LPS-induced ALI mice model, with negligible toxicity in vivo.
